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In the 1970s and 1980s, the aminoglycoside antibiotics were a key antibiotic group in the treatment of serious Gram-negative infections. With the introduction of new beta-lactam agents with pronounced Gram-negative activity during the 1980s, the use of aminoglycosides waned as the less toxic beta-lactams were increasingly used, and this trend continued into the early part of this century \[[@CR1], [@CR2]\]. The declining use of one or more of the aminoglycosides was frequently accompanied by observations of increasing susceptibility among key pathogens \[[@CR3], [@CR4]\] although this relationship has not held true in all studies \[[@CR2]\]. We are now entering a time in which we are encountering rapidly increasing Gram-negative resistance to broad-spectrum beta-lactams including third and fourth generation cephalosporins, beta-lactam---beta-lactamase inhibitor combinations, and the carbapenems. This rising resistance is often mediated by extended-spectrum beta-lactamases (ESBL) and carbapenemases \[[@CR5]--[@CR7]\]. Moreover, the Gram-negative pathogens producing these enzymes are often co-resistant to other important antibiotic classes such as the fluoroquinolones \[[@CR7]--[@CR9]\]. Because of this, it has been suggested by a number of studies that the use of aminoglycosides may be increasing as clinicians search for viable alternative therapies in treating infections with otherwise resistant Gram-negative pathogens \[[@CR10]--[@CR12]\]. The purpose of the present analysis was to assess the level of aminoglycoside use in adults at our institution from 2006 through 2012 and, during that same time period, the level of susceptibility of key Gram-negative pathogens to this antibiotic class.

Methods {#Sec2}
=======

This study was conducted at the Medical University of South Carolina Medical Center, a 709-bed academic medical center located in Charleston, South Carolina, USA. The study was approved by the Medical University of South Carolina Medical Center Institutional Review Board. This article does not contain any studies with human or animal subjects performed by any of the authors. Pertinent data were assembled and analyzed for the period 2006 through 2012. Susceptibility data for the years 1992, 2006, and 2008 through 2012 for *Pseudomonas aeruginosa, Escherichia coli* (non-urine isolates only), and *Klebsiella pneumoniae* were obtained from the hospital's annual antibiograms which are produced in accordance with Clinical and Laboratory Standards Institute (CLSI) guidance \[[@CR13]\]. Thus, no duplicate or surveillance isolates are included. Susceptibility was determined by an automated system (MicroScan WalkAway^®^, Siemens Medical Solutions USA, Inc., Malvern, Pennsylvania, USA) in our Clinical Microbiology Laboratory throughout the period of interest for *E. coli* and *K. pneumoniae* although a change was made to Kirby--Bauer disk diffusion for *P. aeruginosa* in 2007 due to reported inaccuracies of automated systems in determining antibiotic susceptibility of this organism \[[@CR14]\]. Systemic, adult usage data for amikacin, gentamicin and tobramycin for the years 1992 and 2006 through 2012 were obtained from the Department of Pharmacy Services drug administration records. Usage from these records is based on patient billing such that they account for doses dispensed but not returned to the pharmacy (or otherwise wasted) and therefore are, to the best of our knowledge, administered to the patients. Susceptibility data were expressed as percent susceptible and antibiotic usage data were transformed to defined daily doses (DDD) presuming the following typical adult doses: amikacin 15 mg/kg/day; gentamicin and tobramycin 7 mg/kg/day and assuming an 80 kg adult (DDDs = 1.2, 0.56 and 0.56 g, respectively) which are more typical to dosing in this country (as opposed to those DDD definitions provided by the World Health Organization). Usage was normalized for hospital census \[DDD/1,000 patient days (PD)\]. In addition to these data for 2006 through 2012, data were also obtained for 1992 to provide a longer term perspective on potential changes in use and susceptibility. Although little change in total aminoglycoside use or susceptibility of the organisms of interest was noted in the last 4 years of analysis, 2012 values for each was compared to 1992 levels by Student's *t* or Chi-squared tests as appropriate using Excel^®^ for Mac 2011, version 14.3.7 (Microsoft Corporation, Washington, USA).
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Results for antibiotic usage and organism susceptibility for the years of interest are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, respectively. Simple visual inspection revealed little variation in susceptibility of the organisms of interest between 1992 and 2012 or in the last 4 years of observation and changes were not statistically significant. Figure [1](#Fig1){ref-type="fig"} is illustrative of this observation, in this case for *P. aeruginosa*. Changes in susceptibility rates between 1992 and 2006 were all ≤±9% with the exception of *K. pneumoniae* susceptibility to amikacin (−17%). Changes in susceptibility from 1992 to 2012 were also all ≤±9%. Tobramycin remained the most active versus *P. aeruginosa* (% susceptible = 90), while amikacin remained most active versus *E. coli* and *K. pneumoniae* (% susceptible = 98 and 98, respectively). While total aminoglycoside use increased by almost 40% between 1992 and 2012, most of that increase occurred between 2006 and 2008 with only a 1% change in total DDD/1,000 PD between 1992 and 2006 and a 3% increase occurring between 2008 and 2012, indicating stable levels of use during that final 5-year period. The mix of aminoglycosides used did change between 1992 and later years from a predominance of amikacin and gentamicin use to predominant tobramycin use.Table 1Aminoglycoside usage for the years 1992 and 2006 through 2012 (defined daily doses/1,000 patient days)AminoglycosideYear% Change199220062007200820092010201120121992 versus 20122006 versus 2012Amikacin41.23.45.04.911.64.610.74.7−88.539.2Gentamicin46.516.614.224.621.420.723.122.9−50.538.3Tobramycin32.398.893.1133.1126.0121.1130.6140.0333.041.7Total120.0118.8112.2162.6159.0146.4164.3167.739.741.2*P* ^†^----------------0.5280.135^†^Student's *t* test; absolute change in DDD/1,000 PDTable 2Susceptibility to Aminoglycosides Over Time (% susceptible)AminoglycosideYear1992200620082009201020112012*P* ^†^*Pseudomonas aeruginosan* ^a^306379197235126194180 Amikacin898686889089840.382 Gentamicin717081858587800.439 Tobramycin979187909194900.777*Escherichia colin* ^a^225190161183172161184 Amikacin1009797989899980.617 Gentamicin928685848890890.630 Tobramycin988782838787890.661*Klebsiella pneumoniaen* ^a^166214152163119114113 Amikacin998293949698980.597 Gentamicin878991949497950.600 Tobramycin877988929296920.866^†^Chi-squared test; 1992 versus 2012^a^Number testedFig. 1Susceptibility of *Pseudomonas aeruginosa* over time \[% susceptible with 95% confidence interval (CI)\]
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In distinction to reports from other centers, we observed little change in the utilization of aminoglycosides in our institution in recent years (2008--2012) \[[@CR1], [@CR2]\]. Total aminoglycoside usage did increase almost 40% as compared to 1992 levels, however, and the make-up of total usage changed from amikacin predominance to tobramycin predominance over that time period. Nonetheless, as compared to use of other antibiotics for Gram-negative infections at the Medical University of South Carolina Medical Center, the use of aminoglycosides is considerably lower. For purposes of comparison, our 2012 annual usage of piperacillin/tazobactam and meropenem were 228.5 and 595.4 DDD/1,000 PD, respectively (with DDDs defined as 1.5 and 20.25 grams, respectively) versus 120 DDD/1,000 PD for all aminoglycosides combined.

Susceptibility of *P. aeruginosa, E. coli* and *K. pneumoniae* to these aminoglycosides did not change significantly over time either in the last few years of observation or compared to 1992. While it has been suggested that there may be an increased interest and, therefore, use of aminoglycoside due to the emergence of wide-spread resistance of Enterobacteriaceae to beta-lactams mediated by ESBLs and carbapenemase-producing Enterobacteriaceae \[[@CR10]--[@CR12]\], neither our observations nor those stemming from analyses using a collection of academic medical centers' data support that theory \[[@CR1], [@CR2]\]. In fact, the latter two studies revealed diminishing use \[[@CR2]\]. In the more recent of these two reports, reflecting use in 29 hospitals, an overall decline of 41% was reported from 2002 to 2009 \[[@CR2]\]. Resistance to aminoglycoside antibiotics occurs through a number of mechanisms including enzymatic modification, decreased cellular penetration, active efflux and target site alterations with the former being most common \[[@CR15]\]. On that basis, it is reasonable to consider aminoglycoside therapy for infections involving Gram-negative pathogens suspected of producing newer ESBLs or carbapenemases. However, the observation that such bacteria often carry resistance determinants to other antibiotic classes, including aminoglycosides, fluoroquinolones and folic acid inhibitors, may undermine that line of thinking \[[@CR7]--[@CR9]\]. The fact that other broad-spectrum antibiotic exposure may represent a risk factor for acquisition and infection by such organisms only exacerbates the challenge of identifying suitable therapy \[[@CR16]\].

The positive aspect of our findings is perhaps that susceptibility of these key Gram-negative pathogens seems to be stable, at least at our institution. This may well be due to low levels of use in comparison with other Gram-negative agents. In fact, tobramycin remains the most active of our routinely tested antibiotics against *P. aeruginosa* while the vast majority of *E. coli* and *K. pneumoniae* are susceptible to amikacin. Thus, the aminoglycosides merit consideration in selecting antibiotic therapy for otherwise resistant Gram-negative pathogens. With our current level of understanding regarding proper aminoglycoside dosing, based upon pharmacodynamics characteristics \[[@CR12]\], aminoglycosides represent potentially effective and relatively safe antibiotics. At the same time, it must be noted that a 2009 publication, reporting susceptibility data for a variety of bacteria including our organisms of interest collected and tested from 1999 through 2008, noted increasing aminoglycoside resistance \[[@CR17]\]. That study collected isolates associated with serious infections from hospitals across the United States \[[@CR17]\]. While levels of aminoglycoside use cannot be ascertained, that report emphasizes the importance of each hospital determining its own circumstances with regard to aminoglycoside susceptibility patterns \[[@CR17]\].

The current study is not without limitations. As this is a single-center analysis, our results cannot be extrapolated to other hospitals or healthcare settings. We limited our investigation to *P. aeruginosa, E. coli* and *K. pneumoniae* as they are all common causes of healthcare associated infections and are often multidrug resistant \[[@CR18]\]. Obviously, a number of other Gram-negative and Gram-positive pathogens are also problematic, multidrug resistant causes of healthcare associated infections and were not considered here. Because we used hospital antibiogram data, there could be an influence of including susceptibilities from both infecting and colonizing organisms on the values, as opposed to only considering organisms associated with documented infections. Further, the exclusion of duplicate isolates in an antibiogram constructed in compliance with CLSI guidance would theoretically ignore what might be more resistant samples thus skewing susceptibility proportion in a favorable way. We did not assess the influence of aminoglycoside "mix" (use of which agent predominated at various times) on resistance trends. Reports from the 1980s indicated that predominant use of amikacin at individual institutions resulted in improved gentamicin and/or tobramycin susceptibility among Gram-negative pathogens without a sacrifice in amikacin susceptibility \[[@CR19], [@CR20]\]. Whether the changes in susceptibility we did observe between 1992 and 2012 in our pathogens of interest, none of which were statistically significant, were related to the change from predominant amikacin--gentamicin use to predominant tobramycin use is unknown. Further, whether these non-statistically significant changes were also clinically insignificant is a matter for consideration.

Conclusion {#Sec5}
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Low levels of aminoglycoside use, accompanied by stable susceptibility patterns in key Gram-negative pathogens, make these agents viable for treatment of serious infections for which other antibiotics may no longer be suitable.
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